May 27, 2014
BioCryst data has favorable read through for Dyax, says Jefferies
On The Fly: Closing Wrap Stocks on Wall Street were higher as investors returned from their holiday weekend.
Medical News Today
A safe and effective treatment for life-threatening angioedema attacks in the emergency department
In angioedema , patients experience a rapid swelling of the skin and subcutaneous tissues - which, in some cases, can lead to airway obstruction and suffocation.
The Motley Fool
Why Dyax Corp. Shares Dipped
So what: According to Dyax's press release this morning, it has filed to sell 8 million shares of common stock at $9.25 per share, an 8.9% discount to yesterday's closing price.
New Sources Of Revenue And Profitability Are In The Future For Dyax
Biotech companies are intriguing as possible investments not only for their potential stock gains, but also for their contributions to help improve and save the lives of individuals.
BRIEF-Pharming and Salix say FDA extended PDUFA date for angioedema drug Ruconest
If you see a comment that you believe is irrelevant or inappropriate, you can flag it to our editors by using the report abuse links.